Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adagene Inc.
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
July 25, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
July 12, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene to Present at Investor Conferences in June
May 22, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
March 07, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
February 27, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
February 09, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
January 04, 2024
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
November 03, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 12, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene to Present at Investor and Scientific Conferences in September
September 07, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
August 31, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
May 04, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Updates to its Board of Directors
April 28, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
April 18, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
March 28, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
March 14, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
March 05, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial
January 09, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
January 05, 2023
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
December 16, 2022
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
November 21, 2022
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
November 10, 2022
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
October 11, 2022
From
Adagene Inc.
Via
GlobeNewswire
Tickers
ADAG
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.